The Brand Name EPTIDE Has Generic Salt :: EPTIFIBATIDE 

EPTIDE  Is From Company Ranbaxy Priced :: Rs. 8148

EPTIDE have EPTIFIBATIDE is comes under Sub class Anti Platelets of  Main Class Hematological System

Main Medicine Class:: Hematological System  Sub Medicine Class :: Anti Platelets 

Indications for Drugs ::

Myocardial infarction, Unstable angina, Angioplasty, Percutaneous coronary intervention (PCI)

Drug Dose ::

Adult: IV: Acute Coronary Syndrome • In patients with normal renal function: The recommended adult dosage is an IV bolus of 180 mcg/kg as soon as possible following diagnosis, followed by a continuous infusion of 2.0 mcg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a PCI the infusion should be continued up to hospital discharge, or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. • In patients with creatinine clearance <50 mL/min: The recommended adult dosage is an IV bolus of 180 mcg/kg as soon as possible following diagnosis, immediately followed by a continuous infusion of 1.0 mcg/kg/min. Percutaneous Coronary Intervention (PCI) • In patients with normal renal function: The recommended adult dosage is IV bolus of 180 mcg/kg administered immediately before the initiation of PCI followed by a continuous infusion of 2.0 mcg/kg/min and a second 180-mcg/kg bolus 10 minutes after the first bolus. Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. • In patients with creatinine clearance <50 mL/min: The recommended adult dose is an IV bolus of 180 mcg/kg administered immediately before the initiation of the procedure, immediately followed by a continuous infusion of 1.0 mcg/kg/min and a second 180-mcg/kg bolus administered 10 minutes after the first. In patients who undergo CABG surgery, Eptifibatide infusion should be discontinued prior to surgery. Renal impairment: Dose reduction may be needed. CrCl (ml/min) <30 Contraindicated. Contraindication ::

Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation.

Drug Precautions ::

Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm3; hemorrhagic retinopathy, drugs affecting haemostasis. Check APTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy. Drug Side Effects ::

Bleeding, hypotension; localised Injection site reaction; thrombocytopaenia; back pain; anaphylaxis; GI, intracranial or pulmonary haemorrhage.

Pregnancy category ::

2

Drug Mode of Action ::  

Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor thus preventing platelet aggregation and thrombosis.

Drug Interactions ::

Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.